Premium
Can the expression of histocompatibility antigen be changed by lithium?
Author(s) -
Kang ByungJo,
Park SangWun,
Chung TaiHo
Publication year - 2000
Publication title -
bipolar disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.285
H-Index - 129
eISSN - 1399-5618
pISSN - 1398-5647
DOI - 10.1034/j.1399-5618.2000.020208.x
Subject(s) - lithium (medication) , human leukocyte antigen , histocompatibility , immunology , medicine , antigen
Objectives: This study attempted to determine whether human leukocyte antigen (HLA) type changes would be caused by lithium.
Methods : A total of 15 patients were chosen as subjects (4 males, 11 females) and completed tests in class I. Eight of the 15 patients completed tests in class II. Their mean age was 27±7 years. For an average of 51±17 days, lithium, 600–1200 mg/day (mean daily dose: 920±211 mg) was administered for the HLA testing and then compared with the HLA type prior to the time the drug was administered. Class I type test was performed according to the Terasaki microcytotoxicity method and class II type by the Erlich polymerase chain reaction method.
Results : Of the 15 subjects, 11 had changes in HLA‐A, B, C types and two of the eight subjects had changes in HLA DR type.
Conclusion : Lithium, in the therapeutic dose, is considered to bring about changes in HLA expressions in as short a time period as 2 months.